The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Concurrent, 3-times daily ultrafractionated radiation therapy and temozolomide for newly inoperable glioblastoma: TEMOFRAC a phase II trial.
P. D. Beauchesnes
No relevant relationships to disclose
G. Faure
No relevant relationships to disclose
G. Noel
No relevant relationships to disclose
T. Schmitt
No relevant relationships to disclose
L. Martin
No relevant relationships to disclose
L. Taillandier
No relevant relationships to disclose
C. D. Carnin
No relevant relationships to disclose